Haleos Labs Limited (HALEOSLABS)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Healthy balance sheet with Debt/Equity of 0.31 and a Piotroski F-Score of 7/9.
• Promoter holding of 71.80% aligns ownership with minority shareholders.
• Profit growth of 21.02% is outpacing sales growth of 12.03%, showing margin expansion.
• PEG of 1.16 suggests the valuation is not excessive if current profit growth is sustainable.
• ROCE of 11.78% is respectable and comfortably above the debt burden.

Concerns

• ROE of 9.69% is mediocre, yet the stock trades at 2.24 times book value.
• Sales growth of 12.03% is much lower than profit growth of 21.02%, so earnings quality needs scrutiny.
• Dividend yield of 0.12% is negligible, leaving investors dependent on capital gains.
• Small market cap of ₹381 Cr and quarterly net profit of ₹7 Cr could mean volatility and limited institutional support.

AI Analysis

I have no interest in owning a business simply because the price has fallen; I want to understand the engine underneath. Haleos Labs is a small pharmaceutical company, with a market cap of ₹381 crore, trading at ₹1,415. On the positive side, the balance sheet is not troubling: debt is only 0.31 times equity, the Piotroski score is 7 out of 9, and ROCE of 11.78% covers the cost of capital modestly. Yet the quality metrics are just mediocre. ROE is 9.69%, and at 2.24 times book value, Mr. Market is asking me to pay a premium for a business that is not compounding at exceptional rates. The growth picture deserves scrutiny. Sales increased 12.03%, but profit increased 21.02%; that kind of gap usually comes from thinner taxes, better margins, or one-off gains, and it is rarely linear. A PEG of 1.16 is reasonable if the 21% profit growth persists, but that is a big "if" for a firm whose quarterly profit is only ₹7 crore. The dividend yield of 0.12% is almost a rounding error, so the investor is fully dependent on capital gains. Promoter holding of 71.80% is good to see, because aligned owners matter. Still, I cannot call this a wonderful franchise. I need a durable moat, an owner-earnings check, and a better margin of safety than the current P/E of 19.19 gives me. Haleos is an interesting compounder candidate, not a proven Buffett-style buy at this price. I would put it on the watchlist and wait for either stronger earnings quality or a lower price.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer